Artificial intelligence (AI) and computational models are significantly advancing biotech research. Cold Spring Harbor Laboratory introduced BATMAN, an AI model trained on a vast TCR-peptide database (BATCAVE) that predicts T cell receptor cross-reactivity, crucial for optimizing cancer immunotherapies and minimizing off-target effects. Meanwhile, the Baker lab designed AI-generated protein binders targeting peptide-MHC complexes to enhance T cell recognition of disease markers, accelerating personalized immunotherapies. Another AI model predicts the translation efficiency of mRNA sequences across cell types, improving design of mRNA-based treatments. These breakthroughs exemplify AI's expanding role in translational medicine and precision therapies.